Improvements in Pap screenings proposed

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

A proposal to tighten up cervical cancer proficiency testing should lead to a decrease in the number of false-negative cases that cross the desks of gynecologic oncologists.

A proposal to tighten up cervical cancer proficiency testing should lead to a decrease in the number of false-negative cases that cross the desks of gynecologic oncologists.

The Centers for Medicare and Medicaid Services has put forth a plan to improve competency testing for pathologists and cytotechnologists who screen Pap tests.

While the proposal does not directly affect treating physicians, it should increase the number of cervical cancer cases that are prevented or that are found in the early stages, commented Carol Brown, MD, chair of the government relations committee for the Society of Gynecologic Oncologists (SGO).

“These changes do potentially benefit the gynecologic oncologist because they should lead to a decrease in the false-negative rate for Pap smears,” Dr. Brown told Oncology News International. Dr. Brown is also the director of the office of diversity programs and an associate attending surgeon, gynecology service, at Memorial Sloan-Kettering Cancer Center in New York.

The proposed rule updates current regulation of Pap studies under the Clinical Laboratory Improvement Amendments of 1988. The proposed rule doubles the number of slides used during the test to 20, calls for the test to be administered biennially rather than annually, and requires an analysis of trends in Pap test failure. The public comment period for the proposal ends on March 17, 2009.

“Our SGO government relations team has done an initial review of the proposed rule regarding proficiency testing for cytotechnologists and pathologists, and we are supportive of the proposed rule. We are not planning on submitting any changes to this (proposed) rule,” Dr. Brown said.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content